Company Description
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus.
In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases.
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Aoife Brennan |
Contact Details
Address: 20 William Street, Suite 145 Wellesley Hills, Massachusetts 02481 United States | |
| Phone | 866 857 2596 |
| Website | climbbio.com |
Stock Details
| Ticker Symbol | CLYM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001768446 |
| CUSIP Number | 28658R106 |
| ISIN Number | US28658R1068 |
| Employer ID | 83-2273741 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President and Director |
| Dr. Susan Altschuller M.B.A., Ph.D. | Chief Financial Officer |
| Cindy J. Driscoll M.B.A. | Senior Vice President of Finance and Principal Accounting Officer |
| Chandra Adams J.D. | Vice President and General Counsel |
| Ashley Jones | Senior Vice President of People and Workforce Strategy |
| Janaki M. Subramanyam M.Sc. | Vice President and Head of Regulatory Affairs |
| Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer |
| Dr. Edgar D. Charles M.D., M.Sc. | Chief Medical Officer |
| Adam Villa | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 8-K | Current Report |
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 5, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 144 | Filing |